PMC:7239011 / 1635-3363 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"27","span":{"begin":1401,"end":1413},"obj":"Gene"},{"id":"28","span":{"begin":39,"end":49},"obj":"Species"},{"id":"29","span":{"begin":1639,"end":1648},"obj":"Chemical"},{"id":"30","span":{"begin":62,"end":72},"obj":"Disease"},{"id":"31","span":{"begin":444,"end":448},"obj":"Disease"},{"id":"32","span":{"begin":461,"end":498},"obj":"Disease"},{"id":"33","span":{"begin":692,"end":696},"obj":"Disease"},{"id":"34","span":{"begin":698,"end":705},"obj":"Disease"},{"id":"35","span":{"begin":734,"end":742},"obj":"Disease"},{"id":"36","span":{"begin":757,"end":843},"obj":"Disease"},{"id":"37","span":{"begin":1008,"end":1016},"obj":"Disease"},{"id":"38","span":{"begin":1018,"end":1022},"obj":"Disease"},{"id":"39","span":{"begin":1024,"end":1034},"obj":"Disease"},{"id":"40","span":{"begin":1036,"end":1044},"obj":"Disease"},{"id":"41","span":{"begin":1100,"end":1113},"obj":"Disease"},{"id":"42","span":{"begin":1115,"end":1175},"obj":"Disease"},{"id":"43","span":{"begin":1376,"end":1381},"obj":"Disease"},{"id":"44","span":{"begin":1383,"end":1390},"obj":"Disease"},{"id":"45","span":{"begin":1392,"end":1399},"obj":"Disease"},{"id":"46","span":{"begin":1437,"end":1450},"obj":"Disease"},{"id":"47","span":{"begin":1452,"end":1527},"obj":"Disease"},{"id":"48","span":{"begin":1561,"end":1574},"obj":"Disease"},{"id":"49","span":{"begin":1589,"end":1611},"obj":"Disease"},{"id":"50","span":{"begin":1694,"end":1702},"obj":"Disease"},{"id":"51","span":{"begin":1704,"end":1713},"obj":"Disease"}],"attributes":[{"id":"A28","pred":"tao:has_database_id","subj":"28","obj":"Tax:64320"},{"id":"A29","pred":"tao:has_database_id","subj":"29","obj":"MESH:D061466"},{"id":"A30","pred":"tao:has_database_id","subj":"30","obj":"MESH:C000657245"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:D010146"},{"id":"A32","pred":"tao:has_database_id","subj":"32","obj":"MESH:D018908"},{"id":"A33","pred":"tao:has_database_id","subj":"33","obj":"MESH:D005076"},{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:D063806"},{"id":"A35","pred":"tao:has_database_id","subj":"35","obj":"MESH:D018908"},{"id":"A36","pred":"tao:has_database_id","subj":"36","obj":"MESH:D005148"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:D006261"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"MESH:D005076"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"MESH:D018771"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"MESH:D003967"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:D018908"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D005148"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D003371"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D004417"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:D000370"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:D018908"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D005148"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D018908"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:D003680"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Feature Typical GBS Dengue-related GBS Zika virus-related GBS COVID SARS related GBS\nGeographical distributionAgeSexPreceding illnessMean time to GBSInitial symptomsDysphagiaSignsFacial diplegiaDysautonomiaAtaxiaRespiratory failureOther cranial nerves involvedLeukopeniaThrombocytopeniaNerve conductionCT chestMRI Brain/spineTreatmentOutcome GlobalAll age groupsMales 1.5 times more affectedRespiratory or gastrointestinal\u003c 6 weeksParesthesia, pain followed by weakness of limbsLess commonAreflexic quadreparesisCommonCommonLess common25%Ocular nervesUncommonUncommonAIDP--IVIG, PlasmapherisisGood, persistent disability in 20%-30% Latin America, IndiaAll age groupsMales:Females EqualFever, rash, myalgia, headache1–30 daysAscending weakness, paresthesia, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonLess commonGlossopharyngeal nerveCommonCommonAIDP, AMSAN--IVIG, PlasmapheresisGood Latin America, Europe, East Asia, North AmericalMiddle age to elderlyMore malesFever, headache, rash, arthralgia, diarrhea, conjunctivitis0–10 daysLimb pains, paresthesia, lower limb weakness, facial weaknessMore commonAreflexic quadri/paraparesisCommon (\u003e50%)Common (up to 30%)Common (up to 70%)Less common3rd cranial nerve--AIDP \u003e AMAN, AMSAN--IVIG, PlasmapheresisGood, half may require ICU care China, Iran, Europe, USAUsually elderlyMore malesFever, cough, dyspnea, ageusia, hyposmia5–14 daysParesthesia, lower limb weakness, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonCommon-Common-AMSAN, AMAN, AIDPPneumonia, interstitial pneumonitisEnhancement of caudal nerve rootsIVIG, Lopinavir, ritonavir, HCQ, Azithromycin,Poor, residual weakness, dysphagia, long ICU stay"}

    LitCovid-PD-FMA-UBERON

    {"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T7","span":{"begin":237,"end":251},"obj":"Body_part"},{"id":"T8","span":{"begin":314,"end":319},"obj":"Body_part"},{"id":"T9","span":{"begin":1094,"end":1104},"obj":"Body_part"},{"id":"T10","span":{"begin":1233,"end":1246},"obj":"Body_part"},{"id":"T11","span":{"begin":1431,"end":1441},"obj":"Body_part"},{"id":"T12","span":{"begin":1622,"end":1627},"obj":"Body_part"}],"attributes":[{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma63820"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma50801"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma7184"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma5865"},{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma7184"},{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma65132"}],"text":"Feature Typical GBS Dengue-related GBS Zika virus-related GBS COVID SARS related GBS\nGeographical distributionAgeSexPreceding illnessMean time to GBSInitial symptomsDysphagiaSignsFacial diplegiaDysautonomiaAtaxiaRespiratory failureOther cranial nerves involvedLeukopeniaThrombocytopeniaNerve conductionCT chestMRI Brain/spineTreatmentOutcome GlobalAll age groupsMales 1.5 times more affectedRespiratory or gastrointestinal\u003c 6 weeksParesthesia, pain followed by weakness of limbsLess commonAreflexic quadreparesisCommonCommonLess common25%Ocular nervesUncommonUncommonAIDP--IVIG, PlasmapherisisGood, persistent disability in 20%-30% Latin America, IndiaAll age groupsMales:Females EqualFever, rash, myalgia, headache1–30 daysAscending weakness, paresthesia, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonLess commonGlossopharyngeal nerveCommonCommonAIDP, AMSAN--IVIG, PlasmapheresisGood Latin America, Europe, East Asia, North AmericalMiddle age to elderlyMore malesFever, headache, rash, arthralgia, diarrhea, conjunctivitis0–10 daysLimb pains, paresthesia, lower limb weakness, facial weaknessMore commonAreflexic quadri/paraparesisCommon (\u003e50%)Common (up to 30%)Common (up to 70%)Less common3rd cranial nerve--AIDP \u003e AMAN, AMSAN--IVIG, PlasmapheresisGood, half may require ICU care China, Iran, Europe, USAUsually elderlyMore malesFever, cough, dyspnea, ageusia, hyposmia5–14 daysParesthesia, lower limb weakness, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonCommon-Common-AMSAN, AMAN, AIDPPneumonia, interstitial pneumonitisEnhancement of caudal nerve rootsIVIG, Lopinavir, ritonavir, HCQ, Azithromycin,Poor, residual weakness, dysphagia, long ICU stay"}

    LitCovid-PD-UBERON

    {"project":"LitCovid-PD-UBERON","denotations":[{"id":"T4","span":{"begin":237,"end":251},"obj":"Body_part"},{"id":"T5","span":{"begin":314,"end":319},"obj":"Body_part"},{"id":"T6","span":{"begin":1100,"end":1104},"obj":"Body_part"},{"id":"T7","span":{"begin":1233,"end":1246},"obj":"Body_part"},{"id":"T8","span":{"begin":1241,"end":1246},"obj":"Body_part"},{"id":"T9","span":{"begin":1437,"end":1441},"obj":"Body_part"},{"id":"T10","span":{"begin":1622,"end":1627},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0001785"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0002101"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0001785"},{"id":"A8","pred":"uberon_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0002101"},{"id":"A10","pred":"uberon_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"Feature Typical GBS Dengue-related GBS Zika virus-related GBS COVID SARS related GBS\nGeographical distributionAgeSexPreceding illnessMean time to GBSInitial symptomsDysphagiaSignsFacial diplegiaDysautonomiaAtaxiaRespiratory failureOther cranial nerves involvedLeukopeniaThrombocytopeniaNerve conductionCT chestMRI Brain/spineTreatmentOutcome GlobalAll age groupsMales 1.5 times more affectedRespiratory or gastrointestinal\u003c 6 weeksParesthesia, pain followed by weakness of limbsLess commonAreflexic quadreparesisCommonCommonLess common25%Ocular nervesUncommonUncommonAIDP--IVIG, PlasmapherisisGood, persistent disability in 20%-30% Latin America, IndiaAll age groupsMales:Females EqualFever, rash, myalgia, headache1–30 daysAscending weakness, paresthesia, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonLess commonGlossopharyngeal nerveCommonCommonAIDP, AMSAN--IVIG, PlasmapheresisGood Latin America, Europe, East Asia, North AmericalMiddle age to elderlyMore malesFever, headache, rash, arthralgia, diarrhea, conjunctivitis0–10 daysLimb pains, paresthesia, lower limb weakness, facial weaknessMore commonAreflexic quadri/paraparesisCommon (\u003e50%)Common (up to 30%)Common (up to 70%)Less common3rd cranial nerve--AIDP \u003e AMAN, AMSAN--IVIG, PlasmapheresisGood, half may require ICU care China, Iran, Europe, USAUsually elderlyMore malesFever, cough, dyspnea, ageusia, hyposmia5–14 daysParesthesia, lower limb weakness, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonCommon-Common-AMSAN, AMAN, AIDPPneumonia, interstitial pneumonitisEnhancement of caudal nerve rootsIVIG, Lopinavir, ritonavir, HCQ, Azithromycin,Poor, residual weakness, dysphagia, long ICU stay"}

    LitCovid-PD-HP

    {"project":"LitCovid-PD-HP","denotations":[{"id":"T11","span":{"begin":444,"end":448},"obj":"Phenotype"},{"id":"T12","span":{"begin":692,"end":696},"obj":"Phenotype"},{"id":"T13","span":{"begin":698,"end":705},"obj":"Phenotype"},{"id":"T14","span":{"begin":744,"end":755},"obj":"Phenotype"},{"id":"T15","span":{"begin":1008,"end":1016},"obj":"Phenotype"},{"id":"T16","span":{"begin":1018,"end":1022},"obj":"Phenotype"},{"id":"T17","span":{"begin":1024,"end":1034},"obj":"Phenotype"},{"id":"T18","span":{"begin":1036,"end":1044},"obj":"Phenotype"},{"id":"T19","span":{"begin":1081,"end":1092},"obj":"Phenotype"},{"id":"T20","span":{"begin":1094,"end":1113},"obj":"Phenotype"},{"id":"T21","span":{"begin":1376,"end":1381},"obj":"Phenotype"},{"id":"T22","span":{"begin":1383,"end":1390},"obj":"Phenotype"},{"id":"T23","span":{"begin":1392,"end":1399},"obj":"Phenotype"},{"id":"T24","span":{"begin":1431,"end":1450},"obj":"Phenotype"},{"id":"T25","span":{"begin":1704,"end":1713},"obj":"Phenotype"}],"attributes":[{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0012531"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0000988"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0003326"},{"id":"A14","pred":"hp_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/HP_0003401"},{"id":"A15","pred":"hp_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/HP_0002315"},{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0000988"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002829"},{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0002014"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0003401"},{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0007340"},{"id":"A21","pred":"hp_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A22","pred":"hp_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/HP_0002094"},{"id":"A23","pred":"hp_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/HP_0041051"},{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0007340"},{"id":"A25","pred":"hp_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/HP_0002015"}],"text":"Feature Typical GBS Dengue-related GBS Zika virus-related GBS COVID SARS related GBS\nGeographical distributionAgeSexPreceding illnessMean time to GBSInitial symptomsDysphagiaSignsFacial diplegiaDysautonomiaAtaxiaRespiratory failureOther cranial nerves involvedLeukopeniaThrombocytopeniaNerve conductionCT chestMRI Brain/spineTreatmentOutcome GlobalAll age groupsMales 1.5 times more affectedRespiratory or gastrointestinal\u003c 6 weeksParesthesia, pain followed by weakness of limbsLess commonAreflexic quadreparesisCommonCommonLess common25%Ocular nervesUncommonUncommonAIDP--IVIG, PlasmapherisisGood, persistent disability in 20%-30% Latin America, IndiaAll age groupsMales:Females EqualFever, rash, myalgia, headache1–30 daysAscending weakness, paresthesia, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonLess commonGlossopharyngeal nerveCommonCommonAIDP, AMSAN--IVIG, PlasmapheresisGood Latin America, Europe, East Asia, North AmericalMiddle age to elderlyMore malesFever, headache, rash, arthralgia, diarrhea, conjunctivitis0–10 daysLimb pains, paresthesia, lower limb weakness, facial weaknessMore commonAreflexic quadri/paraparesisCommon (\u003e50%)Common (up to 30%)Common (up to 70%)Less common3rd cranial nerve--AIDP \u003e AMAN, AMSAN--IVIG, PlasmapheresisGood, half may require ICU care China, Iran, Europe, USAUsually elderlyMore malesFever, cough, dyspnea, ageusia, hyposmia5–14 daysParesthesia, lower limb weakness, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonCommon-Common-AMSAN, AMAN, AIDPPneumonia, interstitial pneumonitisEnhancement of caudal nerve rootsIVIG, Lopinavir, ritonavir, HCQ, Azithromycin,Poor, residual weakness, dysphagia, long ICU stay"}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T37","span":{"begin":16,"end":19},"obj":"Disease"},{"id":"T38","span":{"begin":20,"end":26},"obj":"Disease"},{"id":"T39","span":{"begin":35,"end":38},"obj":"Disease"},{"id":"T40","span":{"begin":39,"end":43},"obj":"Disease"},{"id":"T41","span":{"begin":58,"end":61},"obj":"Disease"},{"id":"T42","span":{"begin":68,"end":72},"obj":"Disease"},{"id":"T43","span":{"begin":81,"end":84},"obj":"Disease"},{"id":"T44","span":{"begin":890,"end":895},"obj":"Disease"},{"id":"T45","span":{"begin":1036,"end":1044},"obj":"Disease"},{"id":"T46","span":{"begin":1248,"end":1252},"obj":"Disease"},{"id":"T47","span":{"begin":1255,"end":1259},"obj":"Disease"},{"id":"T48","span":{"begin":1261,"end":1266},"obj":"Disease"},{"id":"T49","span":{"begin":1548,"end":1553},"obj":"Disease"},{"id":"T50","span":{"begin":1555,"end":1559},"obj":"Disease"}],"attributes":[{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0005502"},{"id":"A39","pred":"mondo_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0018661"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0020348"},{"id":"A45","pred":"mondo_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"},{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0020347"},{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0020349"},{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0020348"},{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0020348"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0020349"}],"text":"Feature Typical GBS Dengue-related GBS Zika virus-related GBS COVID SARS related GBS\nGeographical distributionAgeSexPreceding illnessMean time to GBSInitial symptomsDysphagiaSignsFacial diplegiaDysautonomiaAtaxiaRespiratory failureOther cranial nerves involvedLeukopeniaThrombocytopeniaNerve conductionCT chestMRI Brain/spineTreatmentOutcome GlobalAll age groupsMales 1.5 times more affectedRespiratory or gastrointestinal\u003c 6 weeksParesthesia, pain followed by weakness of limbsLess commonAreflexic quadreparesisCommonCommonLess common25%Ocular nervesUncommonUncommonAIDP--IVIG, PlasmapherisisGood, persistent disability in 20%-30% Latin America, IndiaAll age groupsMales:Females EqualFever, rash, myalgia, headache1–30 daysAscending weakness, paresthesia, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonLess commonGlossopharyngeal nerveCommonCommonAIDP, AMSAN--IVIG, PlasmapheresisGood Latin America, Europe, East Asia, North AmericalMiddle age to elderlyMore malesFever, headache, rash, arthralgia, diarrhea, conjunctivitis0–10 daysLimb pains, paresthesia, lower limb weakness, facial weaknessMore commonAreflexic quadri/paraparesisCommon (\u003e50%)Common (up to 30%)Common (up to 70%)Less common3rd cranial nerve--AIDP \u003e AMAN, AMSAN--IVIG, PlasmapheresisGood, half may require ICU care China, Iran, Europe, USAUsually elderlyMore malesFever, cough, dyspnea, ageusia, hyposmia5–14 daysParesthesia, lower limb weakness, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonCommon-Common-AMSAN, AMAN, AIDPPneumonia, interstitial pneumonitisEnhancement of caudal nerve rootsIVIG, Lopinavir, ritonavir, HCQ, Azithromycin,Poor, residual weakness, dysphagia, long ICU stay"}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":44,"end":49},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T10","span":{"begin":245,"end":251},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"T11","span":{"begin":314,"end":319},"obj":"http://purl.obolibrary.org/obo/UBERON_0000955"},{"id":"T12","span":{"begin":314,"end":319},"obj":"http://www.ebi.ac.uk/efo/EFO_0000302"},{"id":"T13","span":{"begin":1100,"end":1104},"obj":"http://www.ebi.ac.uk/efo/EFO_0000876"},{"id":"T14","span":{"begin":1241,"end":1246},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"},{"id":"T15","span":{"begin":1437,"end":1441},"obj":"http://www.ebi.ac.uk/efo/EFO_0000876"},{"id":"T16","span":{"begin":1622,"end":1627},"obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"Feature Typical GBS Dengue-related GBS Zika virus-related GBS COVID SARS related GBS\nGeographical distributionAgeSexPreceding illnessMean time to GBSInitial symptomsDysphagiaSignsFacial diplegiaDysautonomiaAtaxiaRespiratory failureOther cranial nerves involvedLeukopeniaThrombocytopeniaNerve conductionCT chestMRI Brain/spineTreatmentOutcome GlobalAll age groupsMales 1.5 times more affectedRespiratory or gastrointestinal\u003c 6 weeksParesthesia, pain followed by weakness of limbsLess commonAreflexic quadreparesisCommonCommonLess common25%Ocular nervesUncommonUncommonAIDP--IVIG, PlasmapherisisGood, persistent disability in 20%-30% Latin America, IndiaAll age groupsMales:Females EqualFever, rash, myalgia, headache1–30 daysAscending weakness, paresthesia, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonLess commonGlossopharyngeal nerveCommonCommonAIDP, AMSAN--IVIG, PlasmapheresisGood Latin America, Europe, East Asia, North AmericalMiddle age to elderlyMore malesFever, headache, rash, arthralgia, diarrhea, conjunctivitis0–10 daysLimb pains, paresthesia, lower limb weakness, facial weaknessMore commonAreflexic quadri/paraparesisCommon (\u003e50%)Common (up to 30%)Common (up to 70%)Less common3rd cranial nerve--AIDP \u003e AMAN, AMSAN--IVIG, PlasmapheresisGood, half may require ICU care China, Iran, Europe, USAUsually elderlyMore malesFever, cough, dyspnea, ageusia, hyposmia5–14 daysParesthesia, lower limb weakness, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonCommon-Common-AMSAN, AMAN, AIDPPneumonia, interstitial pneumonitisEnhancement of caudal nerve rootsIVIG, Lopinavir, ritonavir, HCQ, Azithromycin,Poor, residual weakness, dysphagia, long ICU stay"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T6","span":{"begin":1639,"end":1648},"obj":"Chemical"},{"id":"T7","span":{"begin":1650,"end":1659},"obj":"Chemical"}],"attributes":[{"id":"A6","pred":"chebi_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"Feature Typical GBS Dengue-related GBS Zika virus-related GBS COVID SARS related GBS\nGeographical distributionAgeSexPreceding illnessMean time to GBSInitial symptomsDysphagiaSignsFacial diplegiaDysautonomiaAtaxiaRespiratory failureOther cranial nerves involvedLeukopeniaThrombocytopeniaNerve conductionCT chestMRI Brain/spineTreatmentOutcome GlobalAll age groupsMales 1.5 times more affectedRespiratory or gastrointestinal\u003c 6 weeksParesthesia, pain followed by weakness of limbsLess commonAreflexic quadreparesisCommonCommonLess common25%Ocular nervesUncommonUncommonAIDP--IVIG, PlasmapherisisGood, persistent disability in 20%-30% Latin America, IndiaAll age groupsMales:Females EqualFever, rash, myalgia, headache1–30 daysAscending weakness, paresthesia, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonLess commonGlossopharyngeal nerveCommonCommonAIDP, AMSAN--IVIG, PlasmapheresisGood Latin America, Europe, East Asia, North AmericalMiddle age to elderlyMore malesFever, headache, rash, arthralgia, diarrhea, conjunctivitis0–10 daysLimb pains, paresthesia, lower limb weakness, facial weaknessMore commonAreflexic quadri/paraparesisCommon (\u003e50%)Common (up to 30%)Common (up to 70%)Less common3rd cranial nerve--AIDP \u003e AMAN, AMSAN--IVIG, PlasmapheresisGood, half may require ICU care China, Iran, Europe, USAUsually elderlyMore malesFever, cough, dyspnea, ageusia, hyposmia5–14 daysParesthesia, lower limb weakness, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonCommon-Common-AMSAN, AMAN, AIDPPneumonia, interstitial pneumonitisEnhancement of caudal nerve rootsIVIG, Lopinavir, ritonavir, HCQ, Azithromycin,Poor, residual weakness, dysphagia, long ICU stay"}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T17","span":{"begin":0,"end":84},"obj":"Sentence"},{"id":"T18","span":{"begin":85,"end":1728},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Feature Typical GBS Dengue-related GBS Zika virus-related GBS COVID SARS related GBS\nGeographical distributionAgeSexPreceding illnessMean time to GBSInitial symptomsDysphagiaSignsFacial diplegiaDysautonomiaAtaxiaRespiratory failureOther cranial nerves involvedLeukopeniaThrombocytopeniaNerve conductionCT chestMRI Brain/spineTreatmentOutcome GlobalAll age groupsMales 1.5 times more affectedRespiratory or gastrointestinal\u003c 6 weeksParesthesia, pain followed by weakness of limbsLess commonAreflexic quadreparesisCommonCommonLess common25%Ocular nervesUncommonUncommonAIDP--IVIG, PlasmapherisisGood, persistent disability in 20%-30% Latin America, IndiaAll age groupsMales:Females EqualFever, rash, myalgia, headache1–30 daysAscending weakness, paresthesia, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonLess commonGlossopharyngeal nerveCommonCommonAIDP, AMSAN--IVIG, PlasmapheresisGood Latin America, Europe, East Asia, North AmericalMiddle age to elderlyMore malesFever, headache, rash, arthralgia, diarrhea, conjunctivitis0–10 daysLimb pains, paresthesia, lower limb weakness, facial weaknessMore commonAreflexic quadri/paraparesisCommon (\u003e50%)Common (up to 30%)Common (up to 70%)Less common3rd cranial nerve--AIDP \u003e AMAN, AMSAN--IVIG, PlasmapheresisGood, half may require ICU care China, Iran, Europe, USAUsually elderlyMore malesFever, cough, dyspnea, ageusia, hyposmia5–14 daysParesthesia, lower limb weakness, facial weaknessLess commonAreflexic quadri/paraparesisCommonLess commonLess commonCommon-Common-AMSAN, AMAN, AIDPPneumonia, interstitial pneumonitisEnhancement of caudal nerve rootsIVIG, Lopinavir, ritonavir, HCQ, Azithromycin,Poor, residual weakness, dysphagia, long ICU stay"}